azd4017
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00791752)
Timeline
Indications
Mechanism of action
HSD11B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid
- azd4017
- azd4017
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03313297 | Phase 2 | Apr 10, 2018 | University of Leeds |
| NCT03111810 | Phase 2 | May 1, 2017 | AstraZeneca, University of Oxford |
| NCT02017444 | Phase 2 | Apr 1, 2014 | University of Birmingham |
| NCT01173471 | Phase 2 | Dec 1, 2010 | AstraZeneca |
| NCT01096004 | Phase 1 | Mar 1, 2010 | AstraZeneca |
| NCT00841048 | Phase 1 | Feb 1, 2009 | AstraZeneca |
| NCT00799747 | Phase 1 | Dec 1, 2008 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT00791752 | Phase 1 | Nov 1, 2008 | AstraZeneca, University of Gothenburg |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 5 | 2 | 2008 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Gothenburg | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Leeds | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1